Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like The “totonou” effect: physiological and subjective benefits of sauna relaxation December 1, 2023 Photobiomodulation in Alzheimer’s mouse model falls short in preventive impact November 16, 2023 OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention September 1, 2024
OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention September 1, 2024